Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS CV027-031 Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy
2023-506352-24-00Phase 3Completed
- Sponsor
- MyoKardia
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 23
01
Overview
Phase 3, randomised, double-blind trial in hypertrophic cardiomyopathy (HCM) comparing Mavacamten with Placebo (2 arms). Primary endpoints: Change from baseline in KCCQ Clinical Summary Score at Week 48 and Change from baseline in peak VO2 at Week 48. Started May 2024; status: completed.
02
Drugs
mavacamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on 2023-506352-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506352-24-00.